Insider Selling: Insmed (NASDAQ:INSM) CEO Sells $1,562,374.97 in Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 10,699 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $146.03, for a total value of $1,562,374.97. Following the sale, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $43,982,045.55. This represents a 3.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

William Lewis also recently made the following trade(s):

• On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $150.97, for a total value of $1,615,228.03.
• On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The stock was sold at an average price of $147.79, for a total value of $1,979,794.84.
• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The shares were sold at an average price of $156.34, for a total value of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $158.93, for a total transaction of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total transaction of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $166.97, for a total transaction of $1,786,412.03.

Insmed Price Performance

Shares of INSM opened at $140.13 on Friday. The company has a 50 day moving average of $158.58 and a two-hundred day moving average of $165.58. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $212.75. The company has a market cap of $30.21 billion, a price-to-earnings ratio of -21.86 and a beta of 1.13.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The business had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business’s revenue for the quarter was up 152.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.32) EPS. As a group, analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on INSM shares. HC Wainwright restated a “buy” rating and set a $230.00 price target on shares of Insmed in a research note on Monday, February 23rd. UBS Group lowered their target price on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research note on Tuesday, January 6th. Bank of America set a $203.00 target price on shares of Insmed in a research report on Thursday, December 18th. Jefferies Financial Group set a $269.00 price target on shares of Insmed in a research note on Wednesday, December 10th. Finally, TD Cowen set a $241.00 price target on shares of Insmed in a report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Insmed presently has an average rating of “Buy” and an average price target of $207.52.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently modified their holdings of INSM. CIBC Private Wealth Group LLC boosted its position in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the last quarter. CoreCap Advisors LLC purchased a new position in Insmed during the 4th quarter worth approximately $27,000. Stone House Investment Management LLC acquired a new stake in Insmed during the 3rd quarter valued at approximately $29,000. SBI Securities Co. Ltd. lifted its stake in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 166 shares during the period. Finally, GraniteShares Advisors LLC purchased a new stake in shares of Insmed in the 4th quarter valued at $30,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.